Probiotic composition for preventing and / or relieving ozostomia as well as derivative product and application thereof
The inhibition of a variety of pathogenic bacteria through probiotic compositions solves the limitations of traditional bad breath treatment methods, and achieves safe and efficient bad breath reduction and gastrointestinal inflammation improvement.
Patent Information
- Application Number
- CN202411215272.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-30
- Publication Date
- 2024-11-29
AI Technical Summary
The prior art has limitations in the treatment of bad breath, mechanical therapy has short-lived effect, chemotherapy may cause bacterial disorders and adverse reactions, and traditional methods are difficult to effectively inhibit a variety of pathogenic bacteria that cause bad breath.
By inhibiting Flora nucleus and Porphyrin gingivalis by inhibiting Flora nucleus and Porphyrin gingivalis , the growth of Helicobacter pylori and E. coli reduces bad breath and has anti-inflammatory activity.
Effectively inhibit the growth of a variety of pathogenic bacteria, reduce bad breath, improve gastrointestinal inflammation, regulate bacterial flora, and is safe and has no hemolytic effect. It is suitable for preventing and treating oral and gastrointestinal related problems.
Smart Images

Figure CN119040195A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of microorganisms, and in particular relates to a probiotic composition for preventing and / or alleviating halitosis and a derivative product and application thereof. Background Art
[0002] Bad breath is the third largest oral health problem, affecting people's physical and mental health and quality of life. Bad breath mainly comes from the oral cavity. Gram-negative anaerobic bacteria in the oral cavity, such as Porphyromonas gingivalis and Fusobacterium nucleatum, produce volatile sulfur compounds (VSCs) by decomposing and digesting food residues, cells, saliva and blood retained in the oral cavity. The odor is the main cause of oral bad breath. In addition, Helicobacter pylori infection and Escherichia coli infection can both cause non-oral bad breath. Helicobacter pylori is a spiral, microaerophilic Gram-negative bacterium that colonizes the human gastric mucosa and can synthesize urease, which can decompose urea in the stomach to produce ammonia substances, forming a pungent odor and causing bad breath. In addition, Helicobacter pylori infection can easily lead to chronic inflammatory or ulcerative lesions in the stomach, causing abnormal gastric function, such as slowed peristalsis, and food staying in the stomach for a long time and fermenting, so bad breath occurs when burping. Escherichia coli can live in the human intestines. When the body's resistance is reduced, the Escherichia coli in the intestines multiply in large numbers; if it causes acute gastroenteritis, it can cause gastrointestinal disorders; due to the accumulation of food and the continuous fermentation of unpleasant gases, it can also cause bad breath.
[0003] The basic principle of treating halitosis is to reduce the number of odor-producing bacteria and lower the concentration of VSCs. There are two main traditional treatment methods at present: mechanical therapy, including brushing teeth, brushing tongue, scraping tongue and using dental floss; chemical therapy, such as using chlorhexidine, essential oils and other mouthwash products to treat halitosis. Chlorhexidine has a strong and broad-spectrum antibacterial and bactericidal effect, but chlorhexidine tastes spicy and has a burning sensation. In severe cases, there will be adverse reactions, which shows that its safety and mildness are poor. Both traditional mechanical therapy and chemical therapy have great limitations. The treatment effect is short-lived. Once the treatment is stopped, the pathogens will proliferate again. The long-term use of chemical therapy will cause dysbacteriosis. Summary of the invention
[0004] In view of this, the object of the present invention is to provide a probiotic composition, which can prevent and / or reduce bad breath by inhibiting the activities of Fusobacterium nucleatum and Porphyromonas gingivalis in the oral cavity, while inhibiting the activities of Helicobacter pylori in the stomach and Escherichia coli colonizing the intestine, and exerting anti-inflammatory activity.
[0005] The invention provides a probiotic composition, comprising Lactobacillus plantarum strain SLB01, Lactobacillus plantarum strain A21094 and Lactobacillus rhamnosus strain A21149;
[0006] The deposit number of the Lactobacillus plantarum strain SLB01 is GDMCC No: 61178;
[0007] The deposit number of the plant lactobacillus strain A21094 is GDMCC No: 62961;
[0008] The deposit number of the Lactobacillus rhamnosus strain A21149 is GDMCC No: 62226.
[0009] Preferably, the ratio of the viable cell counts of the Lactobacillus plantarum strain SLB01, the Lactobacillus plantarum strain A21094 and the Lactobacillus rhamnosus strain A21149 is (1-10):(1-10):(1-10).
[0010] Preferably, the ratio of the viable cell counts of the Lactobacillus plantarum strain SLB01, the Lactobacillus plantarum strain A21094 and the Lactobacillus rhamnosus strain A21149 is 1:1:1.
[0011] The present invention provides application of the probiotic composition in preparing a product for preventing and / or alleviating bad breath.
[0012] Preferably, the reducing of bad breath comprises inhibiting the infection of Porphyromonas gingivalis, Fusobacterium nucleatum, Helicobacter pylori and Escherichia coli and resisting gastrointestinal inflammation.
[0013] The invention provides an oral care product, wherein the active ingredient comprises the probiotic composition.
[0014] Preferably, the oral care product comprises at least one of the following: toothpaste, mouthwash and mouth freshening spray.
[0015] The invention provides the use of the probiotic composition in inhibiting the growth and proliferation of Porphyromonas gingivalis, Fusobacterium nucleatum, Helicobacter pylori and Escherichia coli in vitro.
[0016] The invention provides application of the probiotic composition in preparing anti-inflammatory drugs.
[0017] The invention provides a medicine for treating halitosis and / or anti-inflammation, wherein the active ingredient comprises the probiotic composition.
[0018] The invention provides a probiotic composition, comprising Lactobacillus plantarum strain SLB01, Lactobacillus plantarum strain A21094 and Lactobacillus rhamnosus strain A21149; the Lactobacillus plantarum strain SLB01 has a deposit number of GDMCC No: 61178; the Lactobacillus plantarum strain A21094 has a deposit number of GDMCC No: 62961; and the Lactobacillus rhamnosus strain A21149 has a deposit number of GDMCC No: 62226. The probiotic composition can effectively inhibit the growth and proliferation of Fusobacterium nucleatum, Porphyromonas gingivalis, Helicobacter pylori and Escherichia coli; specifically, it has a relatively strong inhibitory effect on Fusobacterium nucleatum and Porphyromonas gingivalis, and the diameters of the inhibition zones are 19.5 mm and 20.3 mm respectively; the probiotic composition also has a relatively strong antagonistic effect on Helicobacter pylori and Escherichia coli related to gastrointestinal diseases, and the diameters of the inhibition zones are 12.2 mm and 20.3 mm respectively. The probiotic composition can efficiently form copolymers with Fusobacterium nucleatum and Porphyromonas gingivalis, and the 24h interactive agglutination rates with Fusobacterium nucleatum and Porphyromonas gingivalis are 79.866% and 70.874% respectively. Meanwhile, the hemolytic experiment shows that the probiotic composition has no hemolytic effect, which meets the safety requirements. Therefore, the probiotic combination can be used to prevent and alleviate oral and non-oral halitosis. In addition, the double bacterial spot plate experiment shows that the growth of the three strains of plant lactobacillus SLB01, plant lactobacillus A21094 and rhamnosus lactobacillus A21149 between the two points is not affected, indicating that they do not have obvious competition or inhibition, and can coexist. It is shown by in vitro anti-inflammatory experiment detection that the probiotic composition can also inhibit the expression of interleukin 6 (IL-6) and tumor necrosis factor inflammatory factor (TNF-α) produced by Raw264.7 cells, and has certain anti-inflammatory activity. It can be seen that the probiotic composition improves gastrointestinal inflammation by inhibiting the growth and reproduction of microorganisms that are prone to cause halitosis in the oral cavity, stomach and intestines, thereby regulating gastrointestinal disorders and achieving the purpose of reducing halitosis. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 The colony morphology diagram of three lactobacillus strains involved in the present invention;
[0020] Figure 2 The Gram staining microscopic examination results of the three lactobacillus strains involved in the present invention;
[0021] Figure 3 This is the phylogenetic tree of 16S rDNA gene sequences of three Lactobacillus strains;
[0022] Figure 4 It is the growth curve of compound probiotics;
[0023] Figure 5 This is the result of the double bacteria spot plate experiment;
[0024] Figure 6 This is a graph showing the growth of the probiotic composition on a blood plate;
[0025] Figure 7 This is a graph showing the inhibitory activity of the probiotic composition against pathogenic bacteria. DETAILED DESCRIPTION
[0026] The invention provides a probiotic composition, comprising a Lactobacillus plantarum strain SLB01, a Lactobacillus plantarum strain A21094 and a Lactobacillus rhamnosus strain A21149; the Lactobacillus plantarum strain SLB01 has a preservation number of GDMCC No: 61178; the Lactobacillus plantarum strain A21094 has a preservation number of GDMCC No: 62961; and the Lactobacillus rhamnosus strain A21149 has a preservation number of GDMCC No: 62226.
[0027] In the present invention, the plant lactobacillus strain SLB01, plant lactobacillus strain A21094, and rhamnosus lactobacillus strain A21149 are all isolated from the feces of centenarians, and the corresponding 16S rDNA sequences are shown in SEQ ID NO:3 to SEQID NO:5. The colony characteristics of the plant lactobacillus strain SLB01 and the plant lactobacillus strain A21094 are as follows: the colony surface is smooth, the colony is light yellow, the morphology is short rod-shaped under the microscope, and the Gram staining is positive. The colony characteristics of the rhamnosus lactobacillus strain A21149 are as follows: the colony is round, milky white, the colony is protruding, smooth, the edges are neat, and opaque. Gram staining is positive, and the bacterial body shape is rod-shaped. The plant lactobacillus strain SLB01 is disclosed in the patent with publication number CN112812999A. The plant lactobacillus strain A21094 is disclosed in the patent with publication number CN117618477A. The Lactobacillus rhamnosus strain A21149 is disclosed in patent publication number CN114958658A.
[0028] In the present invention, the viable cell count ratio of the Lactobacillus plantarum strain SLB01, the Lactobacillus plantarum strain A21094 and the Lactobacillus rhamnosus strain A21149 is preferably (1-10):(1-10):(1-10), more preferably (1-5):(1-5):(1-5), and most preferably 1:1:1.
[0029] In the present invention, the Lactobacillus plantarum strain SLB01, the Lactobacillus plantarum strain A21094 and the Lactobacillus rhamnosus strain A21149 have good antibacterial ability against Fusobacterium nucleatum polymorpha, Porphyromonas gingivalis, Helicobacter pylori and Escherichia coli, among which the inhibitory effect on Porphyromonas gingivalis and Escherichia coli is stronger.
[0030] In the present invention, there is no antagonism between the plant lactobacillus strain SLB01, plant lactobacillus strain A21094 and rhamnosus lactobacillus strain A21149, and they can be compositely used. Double bacteria point and half experimental results show that the growth between the two points of plant lactobacillus SLB01, plant lactobacillus strain A21094 and rhamnosus lactobacillus strain A21149 is not affected, indicating that they do not exist obvious competition or inhibitory effect, and can coexist. The hemolytic experiment of the probiotic composition shows that the probiotic composition produces hemolysin in all cases, can not dissolve hemocytes, and has good safety.
[0031] The present invention provides application of the probiotic composition in preparing a product for preventing and / or alleviating bad breath.
[0032] In the present invention, the mitigation of halitosis preferably includes inhibiting infection of Porphyromonas gingivalis, Fusobacterium nucleatum, Helicobacter pylori and Escherichia coli and resisting gastrointestinal inflammation. In an embodiment of the present invention, the probiotic composition can efficiently form copolymers with Fusobacterium nucleatum and Porphyromonas gingivalis, and the 24h cross-agglutination rates with Fusobacterium nucleatum and Porphyromonas gingivalis are 79.866% and 70.874%, respectively. Antibacterial experiments show that the probiotic composition has high inhibitory activity against four pathogens, with obvious inhibition zones, and has the strongest inhibition ability against Porphyromonas gingivalis and Escherichia coli, with inhibition zones reaching 20.3mm. At the same time, it also has obvious antibacterial effects on Fusobacterium nucleatum and Helicobacter pylori. The anti-inflammatory function test results show that the probiotic composition can inhibit the production of tumor necrosis factor α (TNF-α) and interleukin-6 (IL-6) by macrophages.
[0033] The invention provides an oral care product, wherein the active ingredient comprises the probiotic composition.
[0034] In the present invention, the oral care product preferably includes at least one of the following: toothpaste, mouthwash and oral freshening spray. The oral care product is prepared by selecting different excipients according to different types of products. In the oral care product, the total live bacteria concentration of the probiotic composition is not less than 1×10 9 CFU / mg or 1×10 9 CFU / ml, more preferably (5-10)×10 9 CFU / mg or (5~10)×109 CFU / ml.
[0035] The invention provides the use of the probiotic composition in inhibiting the growth and proliferation of at least pathogens among Porphyromonas gingivalis, Fusobacterium nucleatum, Helicobacter pylori and Escherichia coli in vitro.
[0036] In the embodiment of the present invention, the three strains in the probiotic composition are matched according to the ratio of equal viable bacteria, and all have high inhibitory activity against pathogens, with obvious inhibition zones, and have the strongest inhibition ability against Porphyromonas gingivalis and Escherichia coli, with inhibition zones reaching 20.3 mm. At the same time, the probiotic composition also has obvious antibacterial effects on Fusobacterium nucleatum and Helicobacter pylori.
[0037] The invention provides application of the probiotic composition in preparing anti-inflammatory drugs.
[0038] In the present invention, the anti-inflammatory effect includes inhibiting the secretion of IL-6 and / or TNF-α.
[0039] The invention provides a medicine for treating halitosis and / or anti-inflammation, wherein the active ingredient comprises the probiotic composition.
[0040] In the present invention, the dosage form of the drug preferably includes oral preparations, sprays and lozenges. The total live bacteria concentration of the probiotic composition in the drug is not less than 1×10 9 CFU / mg or 1×10 9 CFU / ml, more preferably (5-10)×10 9 CFU / mg or (5~10)×10 9 The dosage of the drug should be taken or sprayed according to the severity of the bad breath.
[0041] The following is a detailed description of a probiotic composition for preventing and / or alleviating halitosis provided by the present invention, and its derivative products and applications, in conjunction with the embodiments. However, they should not be construed as limiting the scope of protection of the present invention.
[0042] Example 1
[0043] Isolation, purification and identification of strains
[0044] Two strains of Lactobacillus plantarum and one strain of Lactobacillus rhamnosus were isolated from the intestinal microbial flora of centenarians. Among them, Lactobacillus plantarum SLB01 was preserved on October 23, 2020, and the preservation number is GDMCC No: 61178. Lactobacillus plantarum A21094 (Lactiplantibacillus plantarumA21094) was preserved on November 11, 2022, and the preservation number is GDMCC No: 62961. Lactobacillus rhamnosus A21149 (Lacticaseibacillus rhamnosus A21149) was preserved on January 20, 2022, and the preservation number is GDMCC No: 62226.
[0045] Preparation of MRS medium: MRS medium: 10.0g of peptone, 10.0g of beef powder, 5.0g of yeast powder, 20.0g of glucose, 2.6g of dipotassium hydrogen phosphate, 2.0g of diammonium hydrogen citrate, 2.0g of sodium acetate, 0.1g of magnesium sulfate, 0.05g of manganese sulfate, 1.0g of Tween 80, distilled water to 1000mL, pH 6.5, when preparing solid culture medium, add 18.0g of agar powder, and sterilize at 121℃ under high pressure for 15min.
[0046] Strain activation: Take out the desired strain glycerol tube from the -80℃ refrigerator, use MRS solid medium for streaking culture, and place the plate in an anaerobic workstation at 37℃ for 1-2 days; streak and activate for two generations to obtain the growth morphology of Lactobacillus plantarum SLB01, Lactobacillus plantarum A21094 and Lactobacillus rhamnosus A21149 on the MRS plate. Pick a single colony on the purified plate for Gram staining, and the microscopic examination is as follows Figure 2 shown. Figure 1 As shown in the figure, the colony of Lactobacillus rhamnosus A21149 is round, milky white, protruding, smooth, with neat edges and opaque; after Gram staining, the color is observed under a microscope, and the strain is rod-shaped and Gram-positive. The colonies of Lactobacillus plantarum SLB01 and Lactobacillus plantarum A21094 are smooth on the surface, light yellow single colonies, with neat edges and opaque, short rod-shaped under a microscope, and Gram staining is positive.
[0047] 16S rDNA identification of strains: After separation and purification, pick the characteristic colonies of Lactobacillus and mix them in 30μL PBS (10mmol / L, pH 7.4) buffer to make a bacterial suspension. Take 1μL of bacterial suspension and add it to the 16S rDNA gene amplification system. The 25μL amplification system is as follows: 1μL bacterial suspension as template, 1μL of primer 27F (5'-AGAGTTTGATCCTGGCTCAG-3', SEQ ID NO: 1) and primer 1492R (5'-CTACGGCTACCTTGTTACGA-3', SEQ ID NO: 2), 12.5μL of 2×Es Taq Mix, 9.5μL of ddH2O, and PCR amplification conditions are 94℃ pre-denaturation for 5min, 94℃ denaturation for 30s, 55℃ annealing for 30s, 72℃ extension for 1min, 30 cycles, and 72℃ final extension for 2min. After amplification, 1% agarose gel electrophoresis was performed. After electrophoresis and comparison with marker DNA, a band of the correct size was found at 1500 bp, indicating that the 16S rRNA gene was successfully amplified. The PCR amplification product was sent to Sangon Biotech (Shanghai) Co., Ltd. for Sanger sequencing. The forward and reverse sequences obtained by sequencing were sheared and manually spliced to obtain the 16SrDNA gene sequences (SEQ ID NO: 3 to SEQ ID NO: 5) of strain SLB01, strain A21094 and strain A21149. The obtained 16S rDNA gene sequences were compared using the ezbiocloud database (https: / / www.ezbiocloud.net / ), and it was found that strains SLB01 and strains A21094 were similar to Lactobacillus plantarum ATCC 14917. T (Lactiplantibacillusplantarum ATCC 14917 T ) have a 100% sequence similarity; strain A21149 and Lactobacillus rhamnosus JCM 1136 T (LacticaseibacillusrhamnosusJCM1136 T ) with a sequence similarity of 99.93%. This indicates that strains SLB01 and strain A21094 belong to Lactobacillus plantarum, and strain A21149 belongs to Lactobacillus rhamnosus. Phylogenetic analysis further confirmed the phylogenetic status of the three strains. The phylogenetic tree based on 16S rRNA gene sequences is shown in Figure 3 shown.
[0048] Growth curve assay:
[0049] The three lactobacilli contained in the combination were streaked on MRS solid medium and cultured at 37°C for 48 hours. A single colony was selected for continuous activation for two generations, and then a single colony was selected for inoculation into MRS liquid medium and cultured at 37°C for 18 hours for activation to obtain seed liquid; the seed liquid was mixed and inoculated into MRS liquid medium at a ratio of 1:1:1 with an inoculum volume of 3% (v / v), and the growth state was detected by a microplate reader, and its growth curve was drawn, as shown in FIG. Figure 4 shown.
[0050] Figure 4 The growth cycle of the composite probiotics is shown: the first 3 hours is the static adaptation period, 3 hours to 10 hours is the logarithmic growth period, OD 600 The nm absorbance value varied greatly and the strain grew rapidly. After 10h to 30h, the growth of the strain tended to be slow and was in a stable period.
[0051] Example 2
[0052] Double bacterial spot plate experiment
[0053] Lactobacillus plantarum SLB01, Lactobacillus plantarum A21094 and Lactobacillus rhamnosus A21149 were streaked on MRS solid medium and cultured at 37°C for 48 hours to obtain single colonies; they were activated for two generations, and single colonies were picked and inoculated into MRS liquid medium and cultured at 37°C for 18 hours to obtain lactobacillus culture liquid. The culture liquid was centrifuged at 8000g for 10 minutes to collect the cells. The cells were washed twice with PBS and resuspended with PBS to OD 600 =0.8±0.05, and obtain the lactobacillus suspension. The three bacterial suspensions were combined in pairs and spotted on a square bacterial culture dish containing MRS solid culture medium, with a spot volume of 5 μL and a control point-plate distance of 1 to 2 mm. After the bacterial suspension was dried, it was anaerobically cultured at 37°C for 24 hours to observe the growth of the strains.
[0054] The growth of strains in pairs is as follows Figure 5 The results showed that the growth of the three strains of Lactobacillus plantarum SLB01, Lactobacillus plantarum A21094 and Lactobacillus rhamnosus A21149 was not affected when they were inoculated with each other, indicating that there was no obvious competition or inhibition between them and they could coexist. The experiment showed that these three strains of probiotics can be used in combination as a composite probiotic.
[0055] Example 3
[0056] Effect of compound probiotics on coaggregation of common oral pathogens
[0057] The specific steps are as follows:
[0058] Preparation of MPYG medium: 35.89 g of Qingdao Haibo MPYG medium was supplemented with 0.5 mL of Tween 80, 0.5 mL of glycerol and 0.25 mL of 0.5% vitamin K1 solution, and heated to dissolve in 1000 mL of distilled water. When preparing solid culture medium, 17 g of agar was added and sterilized by high pressure at 121°C for 15 min.
[0059] Preparation method of oral pathogenic bacteria suspension: Take glycerol tubes of Fusobacterium nucleatum and Porphyromonas gingivalis from -80℃, take 100μL respectively and spread them on MPYG solid culture medium, culture anaerobically at 37℃ for 24h, pick the colony after a single colony grows and streak it on MPYG solid culture medium, and culture anaerobically at 37℃ for 24h to obtain a single colony. Pick a single colony and inoculate it into MPYG liquid culture medium, culture anaerobically at 37℃ for 48h to obtain a bacterial solution. Centrifuge the bacterial solution at 8000g for 10min to obtain the pathogenic bacteria. Wash the oral pathogens twice with PBS and resuspend them in PBS to OD 600 =0.8±0.05, and suspensions of Fusobacterium nucleatum and Porphyromonas gingivalis were obtained.
[0060] (1) Cultivation of compound probiotics
[0061] The three strains of lactobacillus included in the combination were streaked onto MRS solid culture medium and cultured at 37°C for 48 hours; a single colony was picked and inoculated into MRS liquid culture medium, cultured at 37°C for 18 hours for activation, and activated for two generations to obtain an activated solution. The activated solution was mixed and inoculated into MRS liquid culture medium at a ratio of 1:1:1 with an inoculum volume of 3% (v / v), and cultured at 37°C for 18 hours to obtain a third-generation activated bacterial solution. The bacterial solution was centrifuged at 8000g for 10 minutes to collect the bacteria. The bacteria were washed twice with PBS and resuspended with PBS to OD 600 =0.8±0.05, and obtain Lactobacillus suspension.
[0062] (2) Co-culture of oral pathogens and Lactobacillus
[0063] Take 3 mL of the Fusobacterium nucleatum polymorpha bacterial suspension and the Porphyromonas gingivalis bacterial suspension resuspended with PBS obtained in step (1), respectively, and mix them with 3 mL of the Lactobacillus suspension after adjusting the concentration obtained in step (2), and then place them in a 37°C incubator and culture them for 2 h. Determine the absorbance of the supernatant at 600 nm at different times, and calculate the coagulation rate according to formula I.
[0064] The calculation formula of coagulation rate I is as follows:
[0065]
[0066] A x= absorbance of lactobacillus suspension at 0h, A y = absorbance value of pathogenic bacteria at 0h, A mix = absorbance value of mixed th.
[0067] Table 1 Coaggregation rate of compound probiotics and oral pathogens
[0068]
[0069] The results are shown in Table 1. From the results in Table 1, it can be seen that the composite probiotic combination provided by the present invention can efficiently combine with Fusobacterium nucleatum polymorphic subspecies and Porphyromonas gingivalis, and the co-agglutination rate reaches 14.320% to 79.866% within 2 to 24 hours. The probiotic combination has a strong agglutination effect on both pathogens. At 24 hours, the co-agglutination rate with Fusobacterium nucleatum polymorphic subspecies reaches 79.866%, and the co-agglutination rate with Porphyromonas gingivalis reaches 70.874%, indicating that the probiotic combination can effectively inhibit the colonization of these two pathogens in the oral cavity and play a certain protective role in oral health.
[0070] Example 4
[0071] Hemolytic test of probiotic combination
[0072] 1. The bacterial cell culture method of the probiotic combination is the same as that of Example 1, and the specific steps are as follows:
[0073] The three strains of lactobacillus were streaked on MRS solid culture medium, cultured at 37°C for 48h to obtain single colonies; activated for two generations, single colonies were picked and inoculated in MRS liquid culture medium, cultured at 37°C for 18h to obtain activation solution; the activation solution was mixed and inoculated in MRS liquid culture medium at a volume ratio of 1:1:1 with an inoculum amount of 3% (v / v), cultured at 37°C for 18h to obtain activated bacterial solution; the bacterial solution was centrifuged at 8000g for 10min to obtain lactobacillus cells. The lactobacillus cells were washed twice with PBS and resuspended with PBS to OD 600 =0.8±0.05, and obtain Lactobacillus suspension.
[0074] 2. Preparation of blood cell culture medium
[0075] Weigh 29 g of Qingdao Haibo Columbia basal culture medium, 14 g of agar, and 1000 mL of distilled water, shake well, and sterilize at 121° C. for 15 min; when the culture medium after high temperature and high pressure sterilization cools to 50° C., add 5% sterile defibrinated sheep blood, mix well, and pour into a plate.
[0076] 3. Strain culture
[0077] The lactobacillus suspension obtained above was inoculated into the prepared blood cell plate, cultured anaerobically at 37°C, and observed for hemolysis for 24 to 48 hours.
[0078] 4. Experimental results: Figure 6 The blood cell plate shown did not change, indicating that the probiotic combination does not produce hemolysin and cannot dissolve blood cells, thus meeting the safety requirements.
[0079] Example 5
[0080] Experiment on the antibacterial effect of probiotic combination liquid on pathogenic bacteria
[0081] (1) Cultivation of compound probiotic liquid
[0082] The culture method of the bacterial solution was the same as that of Example 3. The activation solution was mixed and inoculated into MRS liquid culture medium at a volume ratio of 1:1:1 and an inoculum amount of 3% (v / v), and cultured at 37° C. for 18 h to obtain an activated bacterial solution.
[0083] (2) Preparation of bacterial suspension of Fusobacterium nucleatum and Porphyromonas gingivalis The same as in Example 2, single colonies were picked and inoculated into MPYG liquid culture medium, and anaerobically cultured at 37° C. for 48 h to obtain activated bacterial suspension.
[0084] (3) Helicobacter pylori culture:
[0085] Qingdao Haibo Columbia basic medium 29g, agar 14g, distilled water 1000mL, sterilized at 121℃ for 15min, add 50mL sterile defibrinated sheep blood when the temperature drops to 50℃ before pouring the plate, mix well and pour the plate. Spread the Helicobacter pylori Sydney strain SS1 strain taken from the strain bank on the Helicobacter pylori solid culture medium, and culture in a 37℃ three-gas incubator (oxygen 5%, carbon dioxide 10%, nitrogen 85%) for 3d to obtain a single colony. After purification twice, scrape the Helicobacter pylori from the blood plate, add it to the PBS buffer, blow it out and mix it, and obtain the Helicobacter pylori bacterial liquid.
[0086] (4) Cultivation of Escherichia coli
[0087] LB medium: 10g of tryptone, 5g of yeast extract, 10g of NaCl, 17g of agar, 1000mL of distilled water, sterilize at 121℃ for 15min, mix well and pour on a plate (liquid LB medium, no agar is needed). Streak the E. coli strain on LB solid medium, culture in a 37℃ incubator for 1d, and activate twice. Pick a single colony from the activated plate and inoculate it in LB liquid medium, culture it in a 37℃ incubator overnight to obtain E. coli liquid.
[0088] Prepare MPYG medium with 1.7% agar content, sterilize it, wait until the temperature drops below 50°C, add 1% (v / v) Fusobacterium nucleatum solution, shake well, and pour it into a square bacterial culture dish; prepare Qingdao Haibo Columbia basic medium with 1.4% agar content, sterilize it, wait until the medium cools to 50°C, add 5% sterile defibrinated sheep blood, and then add 1% (v / v) Helicobacter pylori solution and 1% (v / v) Porphyromonas gingivalis separately, shake well, and pour it into a square bacterial culture dish; prepare LB solid medium with 1.7% agar content, sterilize it, wait until the medium cools to 50°C, add 1% (v / v) Escherichia coli solution, shake well, and pour it into a square bacterial culture dish. After solidification, use a hole puncher to make a hole, add 100μL of compound probiotic solution into the hole, culture at 37°C for 24h, and observe whether there is a transparent circle. The results are as follows Figure 7 As shown, the diameter of the transparent circle is measured, and the results are shown in Table 2:
[0089] Table 2 Inhibitory effect of compound probiotics on pathogenic bacteria
[0090] Pathogen / Group First time (mm) Second time (mm) The third time (mm) Mean(mm) Fusobacterium nucleatum 21 19.5 18 19.5 Porphyromonas gingivalis 19.5 21 20.5 20.3 Helicobacter pylori 11.5 12.5 12.5 12.2 Escherichia coli 18 23 20 20.3
[0091] The experimental results show that the compound probiotics have high inhibitory activity against the pathogens involved in this experiment, with obvious inhibition zones, and have the strongest inhibitory ability against Porphyromonas gingivalis and Escherichia coli, with inhibition zones reaching 20.3 mm. At the same time, the compound probiotics also have obvious antibacterial effects on Fusobacterium nucleatum and Helicobacter pylori.
[0092] Example 6
[0093] Anti-inflammatory function test of compound probiotics
[0094] (1) Bacteria activation and liquid fermentation
[0095] The activation of the composite probiotic strain and the preparation of the bacterial solution were carried out in the same manner as in Example 3. After anaerobic culture at 37°C for 24 hours, the absorbance value (OD 600 ) was 0.5±0.02, centrifuged at 8000 rpm / min for 5 min, and the supernatant was collected. The collected supernatant was sterilized by filtration with a 0.22 μm filter membrane for the determination of anti-inflammatory ability.
[0096] (2) Activation and subculture of mouse Raw264.7 cells
[0097] Raw264.7 cells were cultured in DMEM complete medium (containing 10% fetal bovine serum, 80U / mL penicillin, 0.08mg / mL streptomycin) in a closed cell culture incubator with 5% CO2, 37°C, saturated humidity. The cells were collected and evenly pipetted, counted using a cell counter, and subcultured in bottles. Cells in the logarithmic growth phase were used for subsequent experiments.
[0098] (3) Raw264.7 cell plating and modeling
[0099] After the previous step of culture, discard the culture medium, wash the cells twice with 2mL of sterile PBS, add 2mL of DMEM to resuspend the cells, transfer to a 15mL centrifuge tube, and then wash the culture dish with 2mL of culture medium, fully wash the cells and transfer them together. Centrifuge at 4℃ and 800rpm for 5min to collect the cells, and discard the supernatant. Add appropriate amount of culture medium, count the cells with a cell counting plate, and dilute appropriately according to the number of cells. Each well contains 500,000 cells in 1mL, and culture for 6h.
[0100] Raw264.7 cell modeling, a total of 4 groups are set up as follows:
[0101] Blank control group: only DMEM culture medium (containing 80U / mL penicillin, 0.08mg / mL streptomycin, without 10% fetal bovine serum) 800μL was added; positive control group: DMEM culture medium (containing 80U / mL penicillin, 0.08mg / mL streptomycin, without 10% fetal bovine serum) containing a final concentration of LPS of 50ng / mL was added 800μL; fermentation supernatant experimental group: (400μL DMEM culture medium (containing 80U / mL penicillin, 0.08mg / mL streptomycin, without 10% fetal bovine serum + 400μL bacterial fermentation supernatant) 800μL; fermentation supernatant experimental control group: (400μL DMEM culture medium (containing 80U / mL penicillin, 0.08mg / mL streptomycin, without 10% fetal bovine serum) containing a final concentration of LPS of 50ng / mL + 400μL fermentation medium) 800μL.
[0102] (4) IL-6 and TNF-α factor determination
[0103] The mouse (IL-6) ELISA detection kit and mouse tumor necrosis factor α (TNF-α) ELISA detection kit of Jianglai Biology were used for detection by ELISA instrument according to the operating requirements of the instructions. The inhibition rate was calculated according to formula II.
[0104] The inhibition rate calculation formula II is as follows:
[0105]
[0106] The results are shown in Tables 3 and 4.
[0107] Table 3 Inhibitory effect of compound probiotics on the production of (IL-6) by Raw264.7 cells
[0108]
[0109]
[0110] Table 4 Inhibitory effect of compound probiotics on the production of tumor necrosis factor α (TNF-α) by Raw264.7 cells
[0111]
[0112] The results of related inflammatory factor detection showed that the compound probiotics could effectively inhibit the expression of inflammatory factors IL-6 and TNF-α in Raw264.7 cells, with inhibition rates of 85.47% and 93.11%, respectively. This indicates that the compound probiotics have certain in vitro anti-inflammatory activity and certain anti-inflammatory function.
[0113] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A probiotic composition, characterized in that: Including Lactobacillus plantarum strain SLB01, Lactobacillus plantarum strain A21094 and Lactobacillus rhamnosus strain A21149; The deposit number of the Lactobacillus plantarum strain SLB01 is GDMCC No: 61178; The deposit number of the plant lactobacillus strain A21094 is GDMCC No: 62961; The deposit number of the Lactobacillus rhamnosus strain A21149 is GDMCC No: 62226.
2. The probiotic composition according to claim 1, characterized in that: The ratio of the number of live bacteria among the Lactobacillus plantarum strain SLB01, the Lactobacillus plantarum strain A21094 and the Lactobacillus rhamnosus strain A21149 is (1-10): (1-10): (1-10).
3. The probiotic composition according to claim 1, characterized in that: The ratio of the number of live bacteria among the Lactobacillus plantarum strain SLB01, the Lactobacillus plantarum strain A21094 and the Lactobacillus rhamnosus strain A21149 is 1:1:
1.
4. Use of the probiotic composition according to any one of claims 1 to 3 in the preparation of a product for preventing and / or alleviating bad breath.
5. The application according to claim 4, characterized in that: The halitosis reduction comprises inhibiting infection of Porphyromonas gingivalis, Fusobacterium nucleatum, Helicobacter pylori and Escherichia coli and / or resisting gastrointestinal inflammation.
6. An oral care product, characterized in that: The active ingredient comprises the probiotic composition according to any one of claims 1 to 3.
7. The oral care product according to claim 6, characterized in that: The oral care product comprises at least one of the following: toothpaste, mouthwash and mouth freshening spray.
8. Use of the probiotic composition according to any one of claims 1 to 3 for inhibiting the growth or proliferation of at least one of Porphyromonas gingivalis, Fusobacterium nucleatum, Helicobacter pylori and Escherichia coli in vitro.
9. Use of the probiotic composition according to any one of claims 1 to 3 in the preparation of anti-inflammatory drugs.
10. A drug for treating halitosis and / or anti-inflammation, characterized in that: The active ingredients include the probiotic composition according to any one of claims 1 to 3 and pharmaceutically acceptable excipients.
Citation Information
Cited By
Lactobacillus casei, probiotic preparation for reducing generation of VSCs and application of probiotic preparation
CN119823901A
Lactobacillus casei, probiotic preparation for reducing vscs production and use thereof
CN119823901B
Phytobacterium plantarum HL-PL05 with triple antibacterial effect and application of phytobacterium plantarum HL-PL05
CN121086916A
